Cargando…

Gastric adenosquamous carcinoma producing granulocyte-colony stimulating factor: a case of a rare malignancy

BACKGROUND: A gastric adenosquamous carcinoma (ASC) that produces granulocyte-colony stimulating factor (G-CSF) is an uncommon malignancy with a poor prognosis. Due to the rarity of this lesion, a standard treatment for the disease has not been established. CASE PRESENTATION: We describe a case of a...

Descripción completa

Detalles Bibliográficos
Autores principales: Moro, Kazuki, Nagahashi, Masayuki, Naito, Tetsuya, Nagai, Yu, Katada, Tomohiro, Minagawa, Masahiro, Hasegawa, Jun, Tani, Tatsuo, Shimakage, Naohiro, Usuda, Hiroyuki, Gabriel, Emmanuel, Kawaguchi, Tsutomu, Takabe, Kazuaki, Wakai, Toshifumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5425362/
https://www.ncbi.nlm.nih.gov/pubmed/28493097
http://dx.doi.org/10.1186/s40792-017-0338-7
Descripción
Sumario:BACKGROUND: A gastric adenosquamous carcinoma (ASC) that produces granulocyte-colony stimulating factor (G-CSF) is an uncommon malignancy with a poor prognosis. Due to the rarity of this lesion, a standard treatment for the disease has not been established. CASE PRESENTATION: We describe a case of a 66-year-old male with a G-CSF-producing gastric ASC who presented with severe anemia and leukocytosis. A radical resection was performed, followed by a course of adjuvant chemotherapy. Histopathologic examination revealed that the tumor consisted of areas of both squamous cell carcinoma and adenocarcinoma. Immunohistochemical staining with an anti-G-CSF antibody was also positive. He was started on adjuvant capecitabine and oxaliplatin (CapeOX) 6 weeks after surgery. The patient stopped treatment after 3 months due to his own preference. Eight months following surgery, the patient was found to have diffuse lymph node, liver, and peritoneal metastases. CONCLUSIONS: G-CSF-producing gastric ASC is a rare and aggressive tumor. Because patients are usually diagnosed at an advanced stage, multidisciplinary evaluation and innovative treatments are needed. The rarity of this disease, with its aggressive features, poses a significant challenge in its treatment. In this brief case report, we summarize the management and outcomes of G-CSF-producing gastric ASC.